Therapy of @entity1860 with recombinant XXXX .

@entity1 @entity3692 @entity221 @entity379 @entity1860 @entity3027
Recently, we reported that recombinant interferon-alpha (rIFN-alpha) can induce hematologic remissions and cytogenetic improvement in newly diagnosed Philadelphia (Ph)-positive @entity1860 ( @entity1860 ) @entity1 . Although @entity379 is a structurally distinct molecule, this agent suppresses in vitro hematopoietic progenitor cells in a fashion similar to that of @entity3027 . Therefore, we initiated a study of @entity3692 at doses of 0.25 to 0.5 mg/m2/d intramuscularly in @entity1 with Ph-positive benign-phase @entity1860 . Twenty-six of 30 @entity1 entered in the study were evaluable. Six @entity1 have achieved a complete hematologic response; four, a partial hematologic response. The median follow-up period of @entity1 who are in complete remission is 7.5 months (range, 5 to 12 months). No relapses have occurred among the complete responders. So far, five @entity1 have had cytogenetic improvement with emergence of 5% to 45% diploid cells in the bone marrow. @entity221 and flulike symptoms were the most common side effects, with partial tolerance often developing after about 1 week. The majority of @entity1 tolerated therapy with minimal change in performance status. In conclusion, @entity3692 has demonstrated clinical activity in @entity1860 . On the basis of these observations and the in vitro synergistic growth-inhibitory effects of @entity3027 and @entity379 , we have started trials of combination IFN therapy in @entity1860 @entity1 .
